BioCardia Dirección

Dirección controles de criterios 3/4

El CEO de BioCardia es Peter Altman , nombrado en Jan 2002, tiene una permanencia de 22.58 años. compensación anual total es $746.24K, compuesta por 69.1% salario y 30.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.87% de las acciones de la empresa, por valor de €98.58K. La antigüedad media del equipo directivo y de la junta directiva es de 8.4 años y 7.8 años, respectivamente.

Información clave

Peter Altman

Chief Executive Officer (CEO)

US$746.2k

Compensación total

Porcentaje del salario del CEO	69.1%
Permanencia del CEO	22.6yrs
Participación del CEO	1.9%
Permanencia media de la dirección	8.4yrs
Promedio de permanencia en la Junta Directiva	7.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Peter Altman en comparación con los beneficios de BioCardia?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$9m
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	US$746k	US$516k	-US$12m
Sep 30 2023	n/a	n/a	-US$13m
Jun 30 2023	n/a	n/a	-US$13m
Mar 31 2023	n/a	n/a	-US$12m
Dec 31 2022	US$902k	US$531k	-US$12m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$13m
Dec 31 2021	US$1m	US$488k	-US$13m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$13m
Mar 31 2021	n/a	n/a	-US$13m
Dec 31 2020	US$883k	US$380k	-US$15m
Sep 30 2020	n/a	n/a	-US$16m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$747k	US$363k	-US$15m
Sep 30 2019	n/a	n/a	-US$15m
Jun 30 2019	n/a	n/a	-US$15m
Mar 31 2019	n/a	n/a	-US$14m
Dec 31 2018	US$1m	US$360k	-US$14m
Sep 30 2018	n/a	n/a	-US$14m
Jun 30 2018	n/a	n/a	-US$13m
Mar 31 2018	n/a	n/a	-US$13m
Dec 31 2017	US$372k	US$310k	-US$12m

Compensación vs. Mercado: La compensación total de Peter($USD746.24K) está por encima de la media de empresas de tamaño similar en el mercado German ($USD471.14K).

Compensación vs. Ingresos: La compensación de Peter ha sido consistente con los resultados de la empresa en el último año.

CEO

Peter Altman (57 yo)

22.6yrs

Permanencia

US$746,237

Compensación

Dr. Peter A. Altman, Ph.D. has been Chief Executive Officer and President of BioCardia, Inc. since 2002. Dr. Altman served as an acting Chief Executive Officer of Lumen Therapeutics from 2004 to 2005. He s...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Peter Altman	CEO, President & Director	22.6yrs	US$746.24k	1.87% € 98.6k
David McClung	Chief Financial Officer	8.4yrs	US$469.47k	0.43% € 22.4k
Edward Gillis	Senior Vice President of Devices	3.8yrs	US$326.37k	0.15% € 8.1k

8.4yrs

Permanencia media

61yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 6JU0 es experimentado (8.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Peter Altman	CEO, President & Director	22.6yrs	US$746.24k	1.87% € 98.6k
Jay Moyes	Independent Director	13.6yrs	US$65.29k	0.17% € 9.0k
Richard Krasno	Independent Director	7.8yrs	US$57.79k	0.15% € 7.8k
William Facteau	Independent Director	less than a year	US$24.69k	sin datos
Simon Stertzer	Independent Director	22.6yrs	US$47.55k	4.68% € 246.3k
Jim Allen	Independent Director	4.8yrs	US$49.29k	2.81% € 148.0k
Andrew Blank	Independent Chairman	4.8yrs	US$97.79k	1.58% € 83.2k

7.8yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de 6JU0 se considera experimentada (7.8 años de antigüedad promedio).

BioCardia Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

BioCardia, Inc., Annual General Meeting, May 20, 2024

Insufficient new directors

BioCardia, Inc. Elects Bill Facteau as Class I Director

BioCardia, Inc., Annual General Meeting, Oct 18, 2023

Insider recently bought €164k worth of stock

Insufficient new directors

Recent updates

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BioCardia Regains Full Compliance with Nasdaq Capital Market's Listing Requirements

BioCardia, Inc. Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

BioCardia, Inc. Announces Fda Approves Cardiamp®? Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.

BioCardia, Inc. Submits for FDA Approval of Morph®? DNA™? Steerable Introducer Product Family

BioCardia, Inc. Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

New major risk - Shareholder dilution

First quarter 2024 earnings released: US$0.09 loss per share (vs US$0.17 loss in 1Q 2023)

BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

BioCardia, Inc., Annual General Meeting, May 20, 2024

Full year 2023 earnings released: US$0.55 loss per share (vs US$0.67 loss in FY 2022)

BioCardia, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

BioCardia Receives Determination Letter from the Staff that the Company Fails to Regain Compliance with the MVLS Requirement

BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

New major risk - Market cap size

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $2.75 million.

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $1.3 million.

BioCardia, Inc. Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.17 loss in 3Q 2022)

Insufficient new directors

BioCardia, Inc. Elects Bill Facteau as Class I Director

Biocardia, Inc. Announces Completion of Enrollment in Phase Iii Cardiamp Hf Trial and Plans for Cardiamp Hf Trial Ii

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia, Inc. Announces Clarification and Next Steps on Its Autologous CardiAMP Cell Therapy Programs

Biocardia, Inc. Announces Interim Efficacy Results in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial

BioCardia, Inc., Annual General Meeting, Oct 18, 2023

New major risk - Revenue size

Second quarter 2023 earnings released: US$0.17 loss per share (vs US$0.14 loss in 2Q 2022)

BioCardia, Inc. to Report First Half, 2023 Results on Aug 09, 2023

Biocardia, Inc. Announces Dsmb Recommendation to Pause New Enrollment in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial While Additional Blinded Data Is Collected

BioCardia, Inc. Completes Submission of Cardiamp Cell Therapy System in Heart Failure to Japan's Pharmaceutical Medical Device Agency

Insider recently bought €164k worth of stock

First quarter 2023 earnings released: US$0.17 loss per share (vs US$0.20 loss in 1Q 2022)

BioCardia, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings released: US$0.67 loss per share (vs US$0.75 loss in FY 2021)

BioCardia, Inc. announced that it expects to receive $3.564989 million in funding

BioCardia, Inc. Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

Insufficient new directors

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.16 loss in 3Q 2021)

BioCardia, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Insufficient new directors

Biocardia®, Inc. to Present New Data from Cardiamp Cell Therapy for Heart Failure Pivotal Trial At the Heart Failure Society of America Annual Meeting

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

Second quarter 2022 earnings released: US$0.14 loss per share (vs US$0.20 loss in 2Q 2021)

BioCardia, Inc. to Report First Half, 2022 Results on Aug 10, 2022

BioCardia, Inc. Announces US Patent on Imaging System for Targeting Cardiac Therapies

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.18 loss in 1Q 2021)

BioCardia, Inc. to Report Q1, 2022 Results on May 11, 2022

BioCardia, Inc. Announces FDA Approval of its IND for NK1R+ Mesenchymal Stem Cells

Full year 2021 earnings released: US$0.75 loss per share (vs US$1.48 loss in FY 2020)

Biocardia Receives No Objection Letter from Health Canada, Enabling Company to Expand Cardiamp Cell Therapy Heart Failure Trial into Canada

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

BioCardia®, Inc Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.30 loss in 3Q 2020)

BioCardia, Inc. Announces Data from Its CardiAMP® Cell Therapy Heart Failure Pivotal Trial to Present at the Heart Failure Society of America Annual Meeting 2021 on September 11, 2021

Second quarter 2021 earnings released: US$0.20 loss per share (vs US$0.46 loss in 2Q 2020)

Biocardia Announces Japanese Patent on Imaging System for Targeting Cardiac Therapies

BioCardia Announces Fourth Positive DSMB Review and Recommendation to Continue Phase III Pivotal Cardiamp Cell Therapy Heart Failure Study as Designed

BioCardia to Present CardiAMP Cell Therapy Clinical Trial Data at European Society of Cardiology Heart Failure 2021

First quarter 2021 earnings released: US$0.18 loss per share (vs US$0.67 loss in 1Q 2020)

Full year 2020 earnings released: US$1.48 loss per share (vs US$2.61 loss in FY 2019)